BIO-TECHNE TO PRESENT AT UPCOMING INVESTOR CONFERENCES
Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the following...
Express News | Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to Serve as Independent Chairman of the Board of Directors
Express News | Scaleready Announces $20 Million G-Rex® Grant Program for the Advancement of Cell and Gene Therapy (Cgt) Development and Manufacturing
Bio-Techne's (NASDAQ:TECH) Investors Will Be Pleased With Their Notable 69% Return Over the Last Five Years
When you buy and hold a stock for the long term, you definitely want it to provide a positive return. But more than that, you probably want to see it rise more than the market average. But Bio-Techn
BIO-TECHNE TO PRESENT AT THE 2024 LEERINK PARTNERS HEALTHCARE CROSSROADS CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer will present at the 2024 Leerink...
Citi Downgrades Bio-Techne(TECH.US) to Hold Rating, Raises Target Price to $85
Citi analyst Patrick B Donnelly downgrades $Bio-Techne(TECH.US)$ to a hold rating, and adjusts the target price from $80 to $85.According to TipRanks data, the analyst has a success rate of 48.4% and
Citi Downgrades Bio-Techne to Neutral, Cites Valuation
Demystifying Bio-Techne: Insights From 4 Analyst Reviews
4 analysts have shared their evaluations of Bio-Techne (NASDAQ:TECH) during the recent three months, expressing a mix of bullish and bearish perspectives.The following table encapsulates their recent
Citi: Bio-Techne (TECH.US) rating downgraded from buying to neutral, with a target price of $85.00.
Citi: Bio-Techne (TECH.US) rating downgraded from buying to neutral, with a target price of $85.00.
Bio-Techne Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 2.81% Citigroup → $85 Downgrades Buy → Neutral 05/02/2024 14.9% Benchmark → $95 Reiterates Buy
Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429 For Autosomal Dominant Polycystic Kidney Disease
Bio-Techne And Regulus Therapeutics Announced Continued Technical And Clinical Collaboration Following Regulus' Topline Results From The Second Cohort Of Phase 1B Multiple Ascending Study Of RGLS8429
BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY'S PROPRIETARY TECHNOLOGY
Citigroup Downgrades Bio-Techne to Neutral From Buy, With $85 Price Target
Bio-Techne (TECH) has an average buy rating and a price target range of $65 to $95, according to analysts polled by Capital IQ.
Bio-Techne(TECH.US) Director Sells US$335.38K in Common Stock
$Bio-Techne(TECH.US)$ Director HIGGINS JOHN L sold 4,000 shares of common stock on May 14, 2024 at an average price of $83.8443 for a total value of $335.38K.Source: Announcement What is statement of
Bio-techne Insider Sold Shares Worth $335,377, According to a Recent SEC Filing
John L Higgins, Director, on May 14, 2024, sold 4,000 shares in Bio-techne (TECH) for $335,377. Following the Form 4 filing with the SEC, Higgins has control over a total of 36,608 shares of the compa
Form 144 | Bio-Techne(TECH.US) Director Proposes to Sell 335.38K in Common Stocks
SEC FILLINGS DISCLOSED/ May 14, $Bio-Techne(TECH.US)$ Director JOHN L HIGGINS intends to sell 4,000 shares of its common stock on May 14, with a total market value of approximately $335.38K. Source
Bio-Techne Corporation (TECH) Declined on Weak Q4 Results
5 Stocks at the Forefront of S&P 500 ETF's Latest Rally
BIO-TECHNE TO PRESENT AT THE BofA SECURITIES HEALTH CARE CONFERENCE 2024
MINNEAPOLIS, May 8, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities Health Ca
BIO-TECHNE TO PRESENT AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT)
No Data